MIRIMUS, INC.

Cold Spring Harbor, NY · Founded 2010 · Biotech · Private

Rapid production platform for genetically engineered RNAi rats using CRISPR/Cas9 and RNA interference for preclinical drug testing

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · mirimus.com

Sector: Biotech
Headquarters: Cold Spring Harbor, NY
Founded: 2010
Latest Form D: $2M, Mar 2011
Total capital: $9.5M

Federal grants: $6.2M; 7 awards · 2017–2024; Rank in peer group#4 of 13
Private capital raised: $2M; 2 Form D · last Mar 2011; 188 months since last filing
Federal contracts: $1.3M; 7 awards · Health and Human S; Rank in Biotech#169 of 4373
Granted patents: 2; 13 pending · first 2024; Rank in peer group#8 of 13

Capital timeline

Latest events

Sep 2024Federal grantHealth and Human S · Phase I · Creation of the Next Generation RNAi Therapeutics and an in vivo model for their study$350K
May 2023Federal contractHealth and Human S · Breeding And Genotype Service$21K
May 2023Federal grantHealth and Human S · Phase I · Preclinical Evaluation of a Novel ADAM10 Modulator to Treat ColorectalCancer$398K
Feb 2022Federal contractHealth and Human S · Reagents Needed For Research.$18K
Nov 2021Federal contractHealth and Human S · Radx Tech II: Saliva Pool Testing For High Throughput Detection And Variant Identification$1.2M
May 2021Federal grantHealth and Human S · Phase II · CRISPR/Cas-mediated development of an RNAi rat model system$1M
Apr 2021Federal contractHealth and Human S · Scientific Supplies C.:1242131 [21-007510]$15K
Mar 2011Private capital raisedForm D · SEC · 2nd filing$2M
Jan 2011Private capital raisedForm D · SEC · 1st filing$775

Show 7 earlier federal awards

Apr 2021Federal contractHealth and Human S · Scientific Supplies [21-007463]$15K
May 2020Federal grantHealth and Human S · Phase II · CRISPR/Cas-mediated development of an RNAi rat model system$2M
Aug 2019Federal contractHealth and Human S · Custom Vector Expressions$17K
Aug 2019Federal contractHealth and Human S · Custom Vector Expressions$17K
Aug 2018Federal grantHealth and Human S · Phase I · High efficiency platform for rapid RNAi rat model development$235K
Mar 2018Federal grantHealth and Human S · Phase II · Next generation CRISPR/Cas9-RNAi mouse models for accelerated drug discovery research$752K
Apr 2017Federal grantHealth and Human S · Phase II · Next generation CRISPR/Cas9-RNAi mouse models for accelerated drug discovery research$1.4M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 13 peers

Line = median

Biotech · System

Federal grants#4 · top 31%
Granted patentsBelow median

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants

Prem PremsrirutResearcherExecutive Officer, DirectorLinked by 1 patent · $3.7M in grants as PI
John MaroneyDirectorNamed in SEC Form D filings
Leo GuthartDirectorNamed in SEC Form D filings
Steven WinickDirectorNamed in SEC Form D filings

What it has protected

USPTO · 2 granted of 15

Oct 2, 2025PendingRegulation Of Artificial Mirnas By Endogenous Tissue-specific Mirnas And Methods Of Using The SameUSPTOApplication 19180809
Jul 22, 2025GrantedCompositions and Methods of Generating Novel amiRNAUSPTOUS 12,365,902
Apr 16, 2024GrantedMETHODS OF GENETIC MEDIATED ENGINEERING OF RNAi MODELSUSPTOUS 11,957,114

Show all 15 patent records

Regulation Of Artificial Mirnas By Endogenous Tissue-specific Mirnas And Methods Of Using The SameOct 2, 2025 · Application 19180809Pending
Compositions and Methods of Generating Novel amiRNAJul 22, 2025 · US 12,365,902Granted
METHODS OF GENETIC MEDIATED ENGINEERING OF RNAi MODELSApr 16, 2024 · US 11,957,114Granted
Modified Mirna As A Scaffold For ShrnaJan 15, 2015 · Application 14310753Pending
Compositions And Methods Of Generating Novel AmirnaApplication PCTUS2023012483Pending
Regulation Of Artificial Mirnas By Endogenous Tissue-specific Mirnas And Methods Of Using The SameApplication 63382190Pending
Compositions And Methods Of Generating Novel AmirnaApplication 63325207Pending
Methods Of Genetic Mediated Engineering Of Rnai ModelsApplication PCTUS2018062836Pending
CRISPR/Cas9 AND MEDIATED ENGINEERING OF RNAI MODELS AND METHODS OF USEApplication 62591479Pending
Inducible CRISPR/CAS9 And Rnai Systems And Methods Of UseApplication PCTUS2016051992Pending
INDUCIBLE CRISPR/Cas9 AND RNAi SYSTEMS AND METHODS OF USEApplication 62218970Pending
Modified Mirna As A Scaffold For ShrnaApplication PCTUS2014013090Pending
Method And Compositions For Interferon Type I Decoys As A Therapeutic For Interferon AutoantibodiesApplication PCTUS2025013780Pending
Method and Compositions for Interferon type I decoys as a therapeutic for interferon autoantibodiesApplication 63626799Pending
Regulation Of Artificial Mirnas By Endogenous Tissue-specific Mirnas And Methods Of Using The SameApplication PCTUS2023078541Pending

OMICRON BIOCHEMICALS, INC.Similar federal contract value in Biotech · $1.3M in contracts
AM BIOTECHNOLOGIES, LLCSimilar federal contract value in Biotech · $1.3M in contracts
CYTOBANK, INC.Similar federal contract value in Biotech · $1.3M in contracts
CONSEGNA PHARMA INCSimilar federal contract value in Biotech · $1.3M in contracts
MYEXPOSOME INCSimilar federal contract value in Biotech · $1.3M in contracts
INSILICOM LLCSimilar federal contract value in Biotech · $1.3M in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.